NCT01872182View on ClinicalTrials.gov

Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome

PHASE3TerminatedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Abdominal Obesity Metabolic Syndrome
Interventions
DRUG

ALS-L1023

daily twice for 12 weeks

DRUG

placebo

daily twice for 12 weeks

Trial Locations (1)

Unknown

5 Institutions, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT01872182 - Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome | Biotech Hunter | Biotech Hunter